glp-1 pregnancy From JAMA: #GLP-1 receptor agonist exposure with discontinuation before or during early #pregnancy was associated with greater gestational weight gain and increased risk of preterm delivery, gestational #diabetes, and hypertensive disorders. https://ja GLP-1 medications like Ozempic, Wegovy

Still in clinical trials, this triple agonist has shown remarkable results in early studies

These trials assessed not only their effectiveness but also their safety and potential side effects

[DOI] [PMC free article] [PubMed] [Google Scholar] 79.Hoffman S, Alvares D, Adeli K

FDA approvals now encompass chronic kidney disease indications for some agents, obstructive sleep apnea treatment and metabolic dysfunction associated steatotic liver disease for select products

Breast adenocarcinoma Prostate adenocarcinoma Non-small cell lung cancer (NSCLC) Colorectal adenocarcinoma Hepatocellular carcinoma (liver cancer) Renal cell carcinoma Pancreatic adenocarcinoma Half of the participants started a GLP-1 medication semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide after their cancer diagnosis

However, most report that these side effects go away after a few days or weeks